Morphinum Hydrochloricum Teva (Morphine Hydrochloride)

Morphine Hydrochloride, the active ingredient in Morphinum Hydrochloricum Teva, is an opioid analgesic presented as a sterile injectable solution for intra‑articular, intravenous, and peri‑articular use. It is employed to manage severe acute pain and post‑operative pain in adult patients requiring rapid, potent analgesia.

GNH USA supplies Morphinum Hydrochloricum Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Morphine Hydrochloride is an opioid analgesic used in the management of pain conditions that require strong, rapid relief. - Severe acute pain: provides rapid, potent analgesia for patients experiencing intense, sudden pain. - Post‑operative pain: reduces pain intensity after surgical procedures, facilitating recovery. - Intra‑articular or peri‑articular administration: delivers targeted analgesia for joint or tissue procedures where local pain control is needed.

Morphine Hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: feeling of sickness often leading to vomiting. - Constipation: reduced bowel movements and hard stools. - Drowsiness: increased sleepiness or reduced alertness. - Sweating: excessive perspiration unrelated to temperature.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure causing dizziness or fainting. - Anaphylaxis: a rare allergic reaction with hives, swelling, and airway compromise.

When using Morphine Hydrochloride, clinicians should observe several safety measures to minimize risks. - Assess pain level: determine severity before initiating therapy. - Monitor respiratory function: observe breathing rate and oxygen saturation regularly. - Avoid use in severe respiratory depression: contraindicated in patients with compromised breathing. - Use caution in renal or hepatic impairment: dose adjustments may be required. - Consider opioid tolerance: patients with prior opioid exposure may need higher doses. - Store at ambient temperature: keep in original container, protect from moisture and light.

Morphine Hydrochloride can interact with other medicines, altering its effects or increasing adverse reactions.

Major Interactions (Avoid): - Central nervous system depressants: concurrent use with benzodiazepines or barbiturates may cause profound sedation and respiratory depression. - Monoamine oxidase inhibitors (MAOIs): combined therapy can precipitate severe hypertension or serotonin syndrome. - Other opioids: additive opioid effects increase risk of respiratory depression.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may raise serotonin levels and risk serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole): can increase morphine plasma concentrations. - Diuretics: may enhance hypotensive effects when used together.